Emerging Major Histocompatibility Complex Class I-Related Functions of NLRC5.

Détails

ID Serval
serval:BIB_65A801DDE635
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Emerging Major Histocompatibility Complex Class I-Related Functions of NLRC5.
Périodique
Advances in Immunology
Auteur(s)
Chelbi S.T., Dang A.T., Guarda G.
ISSN
1557-8445 (Electronic)
ISSN-L
0065-2776
Statut éditorial
Publié
Date de publication
2017
Peer-reviewed
Oui
Volume
133
Pages
89-119
Langue
anglais
Résumé
Recent evidence demonstrates a key role for the nucleotide-binding oligomerization domain-like receptor (NLR) family member NLRC5 (NLR family, CARD domain containing protein 5) in the transcriptional regulation of major histocompatibility complex (MHC) class I and related genes. Detailed information on NLRC5 target genes in various cell types and conditions is emerging. Thanks to its analogy to CIITA (class II major MHC transactivator), a NLR family member known for over 20 years to be the master regulator of MHC class II gene transcription, also the molecular mechanisms underlying NLRC5 function are being rapidly unraveled. MHC class I molecules are crucial in regulating innate and adaptive cytotoxic responses. Whereas CD8+ T cells detect antigens presented on MHC class I molecules by infected or transformed cells, natural killer (NK) lymphocytes eliminate target cells with downregulated MHC class I expression. Data uncovering the relevance of NLRC5 in homeostasis and activity of these two lymphocyte subsets have been recently reported. Given the importance of CD8+ T and NK cells in controlling infection and cancer, it is not surprising that NLRC5 is also starting to emerge as a central player in these diseases. This chapter summarizes and discusses novel insights into the molecular mechanisms underlying NLRC5 activity and its relevance to pathological conditions. A thorough understanding of both aspects is essential to evaluate the clinical significance and therapeutic potential of NLRC5.

Mots-clé
Adaptive Immunity, Animals, CD8-Positive T-Lymphocytes/immunology, Gene Expression Regulation, Genes, MHC Class I, Humans, Immunity, Innate, Immunologic Surveillance, Infection/immunology, Intracellular Signaling Peptides and Proteins/metabolism, Killer Cells, Natural/immunology, Neoplasms/immunology, CD8(+) T cells, CIITA, MHC class I, NK cells, NLR, NLRC5
Pubmed
Création de la notice
28/02/2017 19:10
Dernière modification de la notice
20/08/2019 14:21
Données d'usage